Clinical Use of Ultrasensitive Cardiac Troponin I Assay in Intermediate- and High-Risk Surgery Patients
Table 4
Events stratified by postoperative troponin peak level during the follow-up period.
All patients (%)
Troponin ≥ 0.04 µg/L (%)
Troponin < 0.04 µg/L (%)
OR (95% CI)
Primary outcome
16 (11.3)
15 (31.9)
1 (1.1)
44.06 (5.60–346.9)
<0.001
Cardiac death
2 (1.4)
2 (4.3)
0
10.5 (0.5–218.97)*
0.19
Nonfatal cardiac arrest
2 (1.4)
1 (2.1)
1 (1.1)
2.04 (0.12–33.40)
1.00
Nonfatal MI
14 (9.9)
14 (29.8)
0
82.67 (4.87–1402.27)*
<0.001
Secondary outcome
28 (19.7)
17 (36.2)
11 (11.6)
4.32 (1.82–10.28)
0.001
Death
9 (6.3)
6 (12.8)
3 (3.2)
4.48 (1.07–18.82)
0.06
Nonfatal stroke
5 (3.5)
0
5 (5.3)
0.17 (0.01–3.11)*
0.17
Congestive heart failure
12 (8.5)
9 (19.1)
3 (3.2)
7.26 (1.86–28.30)
0.002
Atrial fibrillation
7 (4.9)
6 (12.8)
1 (1.1)
13.75 (1.60–117.92)
0.005
Coronary revascularization
1 (0.7)
1 (2.1)
0
6.16 (0.25–150.94)*
0.33
OR: odds ratio; CI: confidence interval; MI: myocardial infarction. value indicates differences between patients with and without troponin elevation. Adjusted by adding 0.5 in each cell in case of zero frequency.
